Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study
- PMID: 30158811
- PMCID: PMC6094528
- DOI: 10.4103/jhrs.JHRS_92_17
Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study
Abstract
Context: Gonadotropin-releasing hormone (GnRH) antagonists in fixed or flexible regimens are used for prevention of premature luteinizing hormone (LH) surge, however, data comparing these regimens in stimulated intrauterine insemination (IUI) cycles are lacking.
Aims: The aim of this study is to evaluate the effectiveness of GnRH antagonists in fixed and flexible regimens on the rate of premature luteinization (PL) and ovulation rate in sequential clomiphene-gonadotropin controlled ovulation-IUI cycles.
Settings and design: This study was conducted at tertiary care center; this was randomized controlled study.
Materials and methods: A total of 45 infertile women randomized into three groups of 15 each received clomiphene citrate + human menopausal gonadotrophin. GnRH antagonist was added according to fixed (n = 15) and flexible (n = 15) protocol. No antagonist in control group (n = 15). PL was defined as LH level ≥10 mIU/ml and progesterone level ≥1.0 ng/ml.
Statistical analysis: Mean values compared using the Student's t-test or one-way analysis of variance. Categorical variables distribution tested using either Pearson's Chi-square or Fisher's exact test as appropriate.
Results: Of a total of 45 women, 58% (n = 26) presented with primary and 42% (n = 19) secondary infertility with mean age of 30.8 ± 3.43 years and BMI 26.57 ± 3.22 kg/m2. Fixed regimen (3.7%) showed most reduction in PL compared to flexible (15.38%, P = 0.33) or control (36.67%, P = 0.004). On human chorionic gonadotropin day, mean LH (P = 0.002) and progesterone (P = 0.079) levels in fixed, flexible, and control groups were as follows: 5.04 ± 5.47 mIU/ml, 3.95 ± 4.16 mIU/ml, 9.57 ± 7.91 mIU/ml, and 0.409 ± 0.320 ng/ml, 0.579 ± 0.727 ng/ml, and 1.033 ± 1.022 ng/ml, respectively. Ovulation (P = 0.813) and pregnancy rates (P = 0.99) were 88.9%, 84.6%, and 90% and 22.2%, 19.23%, and 10% in fixed, flexible, and control groups, respectively.
Conclusions: Addition of antagonist in any regimen appears to lower PL rates and improve pregnancy rates in controlled ovarian stimulation and IUI cycles.
Keywords: Clomiphene-gonadotropin; fixed regimen; flexible regimen; gonadotropin-releasing hormone antagonist; intrauterine insemination; premature luteinization.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial.Hum Reprod. 2006 Mar;21(3):632-9. doi: 10.1093/humrep/dei386. Epub 2005 Dec 16. Hum Reprod. 2006. PMID: 16361296 Clinical Trial.
-
GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial.Hum Reprod. 2007 Jan;22(1):101-8. doi: 10.1093/humrep/del337. Epub 2006 Oct 10. Hum Reprod. 2007. PMID: 17032732 Clinical Trial.
-
Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.Taiwan J Obstet Gynecol. 2019 Mar;58(2):234-238. doi: 10.1016/j.tjog.2019.01.012. Taiwan J Obstet Gynecol. 2019. PMID: 30910145
-
Antagonist protocol versus clomiphene in unexplained infertility: A randomized controlled study.Taiwan J Obstet Gynecol. 2016 Jun;55(3):326-30. doi: 10.1016/j.tjog.2016.04.006. Taiwan J Obstet Gynecol. 2016. PMID: 27343309 Clinical Trial.
-
Effect of gonadotropin-releasing hormone antagonists on intrauterine insemination cycles in women with polycystic ovary syndrome: a meta-analysis.Gynecol Endocrinol. 2014 Apr;30(4):255-9. doi: 10.3109/09513590.2013.863862. Epub 2013 Dec 3. Gynecol Endocrinol. 2014. PMID: 24299151 Review.
Cited by
-
Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD005356. doi: 10.1002/14651858.CD005356.pub3. Cochrane Database Syst Rev. 2021. PMID: 34739136 Free PMC article.
References
-
- Cantineau AE, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility. Cochrane Database Syst Rev. 2007;18:CD005356. - PubMed
-
- Verhulst SM, Cohlen BJ, Hughes E, Te Velde E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev. 2006;18:CD001838. - PubMed
-
- Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet. 2005;365:1807–16. - PubMed
-
- Dutch IUI Study Group. Cantineau AE, Cohlen BJ. The prevalence and influence of luteinizing hormone surges in stimulated cycles combined with intrauterine insemination during a prospective cohort study. Fertil Steril. 2007;88:107–12. - PubMed
-
- Lambalk CB, Leader A, Olivennes F, Fluker MR, Andersen AN, Ingerslev J, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: Results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod. 2006;21:632–9. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources